

tion unknown, and the published trials do not allow any conclusion about its efficacy (let alone its effectiveness or cost effectiveness). In its defence it does seem to be very safe—and any safe, effective compound used for osteoarthritis could do much good, even if the effect size is small. However, given the confusion we cannot recommend its wholesale use. We need large clinical trials, without company interference.

Jiri Chard *research assistant*

Paul Dieppe *director*

(p.dieppe@bristol.ac.uk)

MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Bristol BS8 2PR

- 1 Kelly GS. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. *Alternative Med Rev* 1998;3:27-39.
- 2 Adams ME. Hype about glucosamine. *Lancet* 1999;354:353-4.
- 3 Towheed TE, Anastassiades TP. Glucosamine therapy for osteoarthritis. *J Rheumatology* 1999;26:2294-7.
- 4 Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. *Osteoarthritis Cartilage* 1998;6:427-34.
- 5 Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. *Lancet* 2001;357:251-6.

- 6 Hughes RA, Carr AJ. A randomised, double-blind, placebo-controlled trial of glucosamine to control pain in osteoarthritis of the knee. *Arthritis Rheumatism* 2000;43:1903.
- 7 Reichelt A, Forster KK, Fischer M, Rovati LC, Setnikar I. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. *Arzneimittel-Forschung* 1994;44:75-80.
- 8 Vetter G. [Topical therapy of arthroses with glucosamines]. *Munchener Medizinische Wochenschrift* 1969;111:1499-1502.
- 9 Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheumatism* 1998;41:778-99.
- 10 Dieppe P. What is the relationship between pain and osteoarthritis? *Rheumatology in Europe* 1998;27:55-6.
- 11 Creamer P, Lethbridge-Cejku M, Hochberg MC. Factors associated with functional impairment in symptomatic knee osteoarthritis. *Rheumatology* 2000;39:490-6.
- 12 McAlindon TE, LaValley MP, Gulin JP, Felson D. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. *JAMA* 2000;283:1469-75.
- 13 Delafuente JC. Glucosamine in the treatment of osteoarthritis. *Rheum Dis Clin N Am* 2000;26:1-11.
- 14 Chard JA, Tallon D, Dieppe PA. Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. *Ann Rheum Dis* 2000;59:414-8.
- 15 Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. *Arch Intern Med* 1994;154:157-63.
- 16 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-34.
- 17 Egger M, Zellweger-Zahner T, Schneider M, Junker, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. *Lancet* 1997;350:326-9.

Twenty years of AIDS, and no end in sight

A BMJ theme issue will refocus attention on this catastrophic epidemic

A Martian researcher is sent to earth. His mission is to assess a pandemic sweeping the southern hemisphere. On returning to Mars he files his report: “Human beings are undergoing one of the greatest catastrophes in recorded history. The epidemic rages far beyond their control and is steadily gaining momentum. Widespread misery, the devastation of communities, and death outpace the inconsequential expenditures of governments in denial. Nothing stands in its way.”

All this began without fanfare. In 1981 the *Morbidity and Mortality Weekly Report* published a small case series of five gay men in Los Angeles who had *Pneumocystis carinii*—a rare form of pneumonia usually found in people with immune dysfunction.¹ Since then, the disease has left 23 million dead; it will have killed 55 million by 2010. Africa suffers most of the disease burden. India is next in line.

Why did the Martian’s report fail to mention the United Nations Secretary General’s call for a \$10bn (£7bn) global health and AIDS fund?² Because the international response has been feeble. President Bush has pledged only \$200m, when a donation of \$2.5bn would have been consistent with his country’s wealth.³ Worse, as the southern pandemic spirals out of control, northern development assistance has fallen to its lowest level in 20 years.⁴

Drug company discounting of various medications is largely immaterial since the most heavily indebted countries still cannot afford them. And heterosexual transmission rates, and thus incidence, will probably remain high in many southern regions with or without medications.

The HIV tragedy in the south must be foremost on every country’s agenda. The *BMJ* wants to help by pub-

lishing a theme issue in January 2002 on “Global voices on the HIV catastrophe.” By focusing on the south, we aim to boost international and cross-cultural understanding and cooperation. We want to stimulate inquiry, attract high quality research, and collect outstanding educational materials to improve clinical practice among all people infected or affected by HIV.

Among other topics, the issue will include the long term care of AIDS orphans, influencing the social status of women, reducing mother-to-child transmission, the opportunities and pitfalls of an HIV vaccine, and prospects for an effective response by the global health community. We welcome your manuscripts for any section of the journal, but particularly research papers on the HIV epidemic in the developing world. The closing date for submissions is 1 August 2001; please email them to papers@bmj.com.

Gavin Yamey *deputy editor*

wjm, Western Journal of Medicine, 221 Main St, San Francisco, CA 94120-7690, USA (gyamey@bmj.com)

William Rankin *president*

Global AIDS Interfaith Alliance, PO Box 29110, San Francisco, CA 94129-0110, USA

Richard Feachem *director*

Institute for Global Health, University of California San Francisco, 74 New Montgomery, Suite 508, San Francisco, CA 94105, USA

- 1 Pneumocystis pneumonia—Los Angeles. *MMWR Morb Mortal Wkly Rep* 1981 Jun 5;30(21):250-2.
- 2 Brown P. Kofi Annan describes new health fund for developing countries. *BMJ* 2001;322:1265.
- 3 Morin SA. AIDS and George W Bush. *San Francisco Chronicle* 2001 May 28.
- 4 United Nations Conference on Trade Development. *Less developed countries report*. Geneva: Unctad, 2001.

BMJ 2001;322:1440

We ask all editorial writers to sign a declaration of competing interests (bmj.com/guides/confli.shtml#aut). We print the interests only when there are some. When none are shown, the authors have ticked the “None declared” box.